BRD4 Modulates Vulnerability of Triple-negative Breast Cancer to Targeting of Integrin-dependent Signaling Pathways
Overview
Authors
Affiliations
Purpose: Stemming from a myriad of genetic and epigenetic alterations, triple-negative breast cancer (TNBC) is tied to poor clinical outcomes and aspires for individualized therapies. Here we investigated the therapeutic potential of co-inhibiting integrin-dependent signaling pathway and BRD4, a transcriptional and epigenetic mediator, for TNBC.
Methods: Two independent patient cohorts were subjected to bioinformatic and IHC examination for clinical association of candidate cancer drivers. The efficacy and biological bases for co-targeting these drivers were interrogated using cancer cell lines, a protein kinase array, chemical inhibitors, RNAi/CRISPR/Cas9 approaches, and a 4 T1-Balb/c xenograft model.
Results: We found that amplification of the chromosome 8q24 region occurred in nearly 20% of TNBC tumors, and that it coincided with co-upregulation or amplification of c-Myc and FAK, a key effector of integrin-dependent signaling. This co-upregulation at the mRNA or protein level correlated with a poor patient survival (p < 0.0109 or p < 0.0402, respectively). Furthermore, we found that 14 TNBC cell lines exhibited high vulnerabilities to the combination of JQ1 and VS-6063, potent pharmacological antagonists of the BRD4/c-Myc and integrin/FAK-dependent pathways, respectively. We also observed a cooperative inhibitory effect of JQ1 and VS-6063 on tumor growth and infiltration of Ly6G myeloid-derived suppressor cells in vivo. Finally, we found that JQ1 and VS-6063 cooperatively induced apoptotic cell death by altering XIAP, Bcl2/Bcl-xl and Bim levels, impairing c-Src/p130Cas-, PI3K/Akt- and RelA-associated signaling, and were linked to EMT-inducing transcription factor Snail- and Slug-dependent regulation.
Conclusion: Based on our results, we conclude that the BRD4/c-Myc- and integrin/FAK-dependent pathways act in concert to promote breast cancer cell survival and poor clinical outcomes. As such, they represent promising targets for a synthetic lethal-type of therapy against TNBC.
Focal adhesion in the tumour metastasis: from molecular mechanisms to therapeutic targets.
Liu Z, Zhang X, Ben T, Li M, Jin Y, Wang T Biomark Res. 2025; 13(1):38.
PMID: 40045379 PMC: 11884212. DOI: 10.1186/s40364-025-00745-7.
Caragine C, Le V, Mustafa M, Diaz B, Morris J, Muller S Nat Commun. 2025; 16(1):1611.
PMID: 39948336 PMC: 11825950. DOI: 10.1038/s41467-025-56568-5.
Rossi T, Iorio E, Chirico M, Pisanu M, Amodio N, Gallo Cantafio M Cell Prolif. 2024; 57(12):e13730.
PMID: 39223828 PMC: 11628750. DOI: 10.1111/cpr.13730.
Gonzalez-Rodriguez M, Troutman S, Bayle S, Lester D, Grove M, Duckett D Oncogene. 2024; 43(40):2995-3002.
PMID: 39209965 DOI: 10.1038/s41388-024-03144-8.
Vlahopoulos S Int J Mol Sci. 2024; 25(16).
PMID: 39201306 PMC: 11354898. DOI: 10.3390/ijms25168621.